Fintel reports that on November 6, 2024, Raymond James upgraded their outlook for Masimo (NasdaqGS:MASI) from Market Perform ...

Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

In the latest lawsuit, Apple was awarded $250 in damages – the statutory minimum, which was what the company sought in its ...

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO ...

Masimo (Nasdaq:MASI) shares ticked up before hours today on third-quarter results that came in ahead of the consensus ...

Apple won the case, though was only awarded a nominal $250, which is the smallest amount it was possible for the court to order. In other words, yes Masimo did in infringe Apple’s patents, but there ...

We recently published a list of 8 Most Promising Medical Stocks According to Hedge Funds. In this article, we are going to ...

Masimo (NASDAQ:MASI) is set to give its latest quarterly earnings ... All You Need to Know About Masimo Masimo Corp is a global technology company. The company's segment includes healthcare ...

Vanderbilt University Medical Center is launching Masimo Radius VSM™ advanced wireless patient-worn vital signs monitoring ...

Needham analyst Michael Matson maintained a Hold rating on Masimo (MASI – Research Report) today. The company’s shares closed ...

Masimo Corp. ( (MASI) ) has released its Q3 earnings. Here is a breakdown of the information Masimo Corp. presented to its investors. Masimo ...

The consensus rating for Masimo is Buy, based on 2 analyst ratings. With an average one-year price target of $167.5, there's a potential 16.14% upside.